Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin gamma-A6 (PCDHGA6) is a calcium-dependent cell-adhesion protein, a member of the protocadherin gamma gene cluster within the larger cadherin superfamily[1]. It is primarily expressed in the brain, where it is believed to play critical roles in the establishment and function of specific cell-cell connections among neurons[1][2][3]. The gamma cluster, to which it belongs, is characterized by an immunoglobulin-like genomic organization, and produces neural cell adhesion proteins with six extracellular cadherin domains, a transmembrane region, and a common cytoplasmic region[1][2][3]. These molecules engage in both homophilic trans interactions (between neighboring cells) and promiscuous cis interactions (on the same cell), providing remarkable surface diversity critical for neuronal self-recognition and wiring specificity[2][3][4]. PCDHGA6 has been associated with neurodevelopmental disorders such as microcephaly and disorders marked by poor growth and skeletal anomalies[1]. There are currently no approved drugs, established mechanisms of action, or well-defined safety concerns directly related to therapeutically targeting PCDHGA6[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin gamma-A6 (PCDHGA6).